mProX™ Human TLR9 Stable Cell Line

Luo, Lihua. et al. "Liposome Vaccine for Active Regulation of Cellular and Humoral Immunity." Molecular pharmaceutics, 2023.
Significant progress has been made in the development of vaccines, particularly in the fight against viral infections. However, there are still many areas that have not been fully explored, including the use of innovative adjuvants and diversification of vaccine formulations. Effective coordination of humoral and cellular immunity is crucial in vaccine design. In a recent study, the spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or ovalbumin (OVA) were used as antigen models, while CpG DNA was used as an adjuvant to create a multitargeted liposome (LIPO) vaccine. By specifically targeting lymph nodes and the endoplasmic reticulum, this LIPO vaccine was found to significantly enhance the cross-presentation ability of antigen-presenting cells (APCs) and regulate the presentation of exogenous antigens through the ER-associated protein degradation (ERSD) mechanism. In vivo mouse experiments showed that the LIPO vaccine was able to effectively stimulate both humoral and cellular immune responses, triggering immune protection by establishing a strong and enduring germinal center. Additionally, the multifunctionality of this LIPO vaccine has potential for use in various fields, including cancer, viruses, and bacteria, providing valuable insights for future vaccine development and improvement.
Luo, Lihua. et al. "Liposome Vaccine for Active Regulation of Cellular and Humoral Immunity." Molecular pharmaceutics, 2023.
Pubmed: 37856874   DOI: 10.1021/acs.molpharmaceut.3c00536

Thi Hoang Do, Kim. et al. "The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice." Frontiers in cellular and infection microbiology, 2023.
A promising vaccine vector for the respiratory administration, Modified Vaccinia virus Ankara (MVA), has been identified as a potential candidate for inducing protective lung immunity and the development of tertiary lymphoid structure, the bronchus-associated lymphoid tissue (BALT). However, the administration of MVA expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike protein (MVA-SARS-2-S) necessitates a prime-boost approach to induce high levels of anti-Spike antibodies in both serum and bronchoalveolar lavage (BAL). To further enhance immune responses, Toll-like receptor (TLR)-agonists were tested in conjunction with a single dose of intranasally administered MVA-SARS-2-S.
Thi Hoang Do, Kim. et al. "The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice." Frontiers in cellular and infection microbiology, 2023.
Pubmed: 37854858   DOI: 10.3389/fcimb.2023.1259822